Marker Therapeutics (MRKR) Proxy Filing summary

Executive summary

• Special meeting scheduled for March 21, 2025, with voting open until March 20, 2025 at 11:59 PM ET.

• Shareholders can vote online, by phone, email, or in person at the virtual meeting after registering as a Beneficial Holder.

Voting matters and shareholder proposals

• Proposal to approve, per Nasdaq Listing Rule 5635(d), the issuance of shares upon exercise of Private Placement Warrants (5,031,250 shares) and Pre-Funded Warrants (3,247,445 shares) of Common Stock.

• Board recommends voting in favor of the share issuance proposal.

• Other business may be addressed as appropriate during the meeting or any adjournment.

Shareholder rights and capital structure

• Approval would authorize significant new share issuances, potentially impacting capital structure.

• Brokers may exercise discretionary voting on routine matters if instructions are not received 10 days before the meeting, but shareholder instructions will be prioritized if received before the meeting.